Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Sarcoidosis
Interventions: Placebo, Golimumab, Ustekinumab; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more

Conditions: Laryngopharyngeal Reflux
Interventions: Prevacid; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Biliary Tract Neoplasms
Interventions: Durvalumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 12 more

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 4
States / cities: Cullman, Alabama • Tampa, Florida • Boston, Massachusetts + 1 more

Conditions: Asthma
Interventions: AZD8630, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 18
States / cities: Tempe, Arizona • Bakersfield, California • Glendale, California + 11 more

Conditions: Atopic Dermatitis
Interventions: Placebo, PF-04965842, PF04965842; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 52
States / cities: Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more

Conditions: Prurigo Nodularis, Pruritis
Interventions: Vixarelimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 40
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 33 more

Conditions: Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions: VGX-3100, Placebo, Electroporation (EP); Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 22
States / cities: Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more

Conditions: Bleeding, Bruising Face, Swelling Lips & Face
Interventions: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml, Normal Saline 0.9% Infusion Solution Bag; Drug
Lead sponsor: Glasgold Group Plastic Surgery; Other
Eligibility: 40 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Postpartum Preeclampsia, Hypertension in Pregnancy
Interventions: Labetalol Oral Tablet, NIFEdipine ER; Drug
Lead sponsor: Nebraska Methodist Health System; Other
Eligibility: 19 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Constipation
Interventions: Tegaserod; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Timeline: 2006 – 2007
U.S. locations: 59
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Dementia
Interventions: Oral Fasudil 90 mg/day, Oral Fasudil 180 mg/day, Oral Placebo; Drug
Lead sponsor: Woolsey Pharmaceuticals; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Stamford, Connecticut • Lakeland, Florida • Miami Lakes, Florida + 3 more

Conditions: Degenerative Spine Disease, Spinal Stenosis Lumbar
Interventions: Virtual Reality-Based CBT Prehabilitation (VR-CBT), CBT Prehabilitation without Virtual Reality; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Irvine, California • Newport Beach, California

Conditions: Obesity, Gender, Problem of Aging
Interventions: Cardiopulmonary Exercise Stress Test, Climatic-Controlled Cardiopulmonary Exercise Stress Test, Body Composition Evaluation, Pre-Exercise Risk Assessment; Procedure
Lead sponsor: Freeman-Sheldon Research Group, Inc.; Other
Eligibility: 35 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1972
U.S. locations: 1
States / cities: Buckhannon, West Virginia

Conditions: Pulmonary Arterial Hypertension, Insulin Resistance
Interventions: Nutrition and Exercise; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Mood
Interventions: Botulinum Neurotoxin, Placebo; Drug
Lead sponsor: DeNova Research; Other
Eligibility: 10 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Neck Pain
Interventions: Supine Thoracic Spine Manipulation, Prone Thoracic Spine Manipulation; Other
Lead sponsor: A.T. Still University of Health Sciences; Other
Eligibility: 22 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Postmenopausal Vulvovaginal Atrophy
Interventions: WC3011 Estradiol Vaginal Cream, Vehicle; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 70
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 58 more

Conditions: Post-operative Pain, Total Shoulder Arthroplasty, Osteoarthritis of the Shoulder, Pain Management
Interventions: Liposomal Bupivicaine 1.3%, Bupivacaine 0.5%; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Cataract, Cataract (Post-operative Cataract Surgery Follow-up)
Interventions: Music and Guided Imagery, Control, Music Only; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Thyroid Eye Disease
Interventions: Efgartigimod PH20 SC, Placebo PH20 SC; Combination Product · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more

Conditions: Post-traumatic Stress Disorder, PTSD
Interventions: Placebo, Brexpiprazole; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 22
States / cities: Los Angeles, California • Riverside, California • San Diego, California + 17 more

Conditions: Obesity
Interventions: Freeze-dried whole-grape powder; Dietary Supplement
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Denton, Texas

Search by objective public record fields.

A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Intravenous Tranexamic Acid During Rhytidectomy

Pulse Oximetry_Performance Testing- PCBA-1 (Printed Circuit Board Assembly)

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

Fasudil fOr redUcing elopemeNt and Spatial Disorientation

VR-Cognitive Behavioral Therapy Prehabilitation for Spinal Deformity Surgery

Work-Related Effects of Heat, Activity, and Fat in Middle Aged Men

Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)

Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction

Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain

Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women

LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs

Randomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

Effect of Whole-grape Powder on Body Composition, Fat and Bone Serum Biomarkers in Postmenopausal Women